Consider 505(b)(2) Pathway [Design Issues]

posted by bebac_fan – US, 2018-05-05 17:08 (935 d 01:45 ago) – Posting: # 18756
Views: 2,281

I think this would need to go through a NDA/505(b)(2) pathway rather than an ANDA.

In this case, comparative efficacy, rather than BE, will be considered pivotal.

Complete thread:

Activity
 Admin contact
21,210 posts in 4,426 threads, 1,481 registered users;
online 3 (0 registered, 3 guests [including 3 identified bots]).
Forum time: Wednesday 17:54 CET (Europe/Vienna)

You can’t fix by analysis
what you bungled by design.    Richard J. Light, Judith D. Singer, John B. Willett

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5